Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Shares of gene editing companies were largely steady in the premarket on Friday after the FDA’s Center for Biologics Research ...

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of the one-time treatments are in the clinic. Lead candidate VERVE-102, a gene-editing ...

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...